FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo Nodularis

Tuesday, May 31, 2022 1 min read

Key Takeaway: FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo Nodularis

Full Press Release Details

FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo Nodularis.